Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Dec 5:13:577.
doi: 10.1186/1471-2407-13-577.

Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis

Jingxu Sun  1 , Yongxi Song, Zhenning Wang, Xiaowan Chen, Peng Gao, Yingying Xu, Baosen Zhou, Huimian Xu
Affiliations
Meta-Analysis

Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis

Jingxu Sun et al. BMC Cancer. .

Abstract

Background: Palliative gastrectomy for patients with advanced gastric cancer remains controversial. The objective of the present meta-analysis was to analyze survival outcomes and establish a consensus on whether palliative gastrectomy is suitable for patients with incurable advanced gastric cancer and which type of patients should be selected to receive palliative gastrectomy.

Methods: A literature search was conducted in PubMed, EMBASE and the Cochrane Library. The results for overall survival in the meta-analysis are expressed as hazard ratios (HRs) with 95% confidence intervals (CIs).

Results: Of 1647 articles and abstracts reviewed, 14 studies with 3003 patients were eligible for the final analysis. The meta-analysis revealed that palliative gastrectomy is associated with a significantly improvement in overall survival (HR 0.56; 95%CI 0.39-0.80; p < 0.002) compared that of patients treated without palliative gastrectomy. An improvement in survival was also observed in patients with stage M1 gastric cancer who received palliative gastrectomy (HR 0.62; 95%CI 0.49-0.78; p < 0.0001), especially those with peritoneal dissemination (HR = 0.76, 95%CI 0.63-0.92), liver metastasis (HR = 0.41, 95%CI 0.30-0.55), or distant lymph-node metastasis (HR = 0.36, 95%CI 0.23-0.59). Combined hepatic resection may be beneficial for patients who under palliative gastrectomy (HR 0.30; 95%CI 0.15-0.61; p = 0.0008). The overall survival of patients who underwent palliative gastrectomy combined with chemotherapy was significantly improved (HR 0.63; 95%CI 0.47-0.84; p = 0.002).

Conclusions: From the results of the meta-analysis, palliative gastrectomy for patients with incurable advanced gastric cancer may be associated with longer survival, especially for patients with stage M1 gastric cancer. Combined hepatic resection for patients with liver metastasis and chemotherapy may be beneficial factors compared to simple palliative gastrectomy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Hazard ratio for overall survival. (PG: palliative gastrectomu; NR: no resection).
Figure 2
Figure 2
Hazard ratio for overall survival of subgroups with different M stages. (PG: palliative gastrectomu; NR: no resection).
Figure 3
Figure 3
Hazard ratio for overall survival influenced by chemotherapy. (C: chemotherapy; CR: combined resection).
Figure 4
Figure 4
Hazard ratio for overall survival of patients with liver metastasis received combined hepatic resection or not. (C: chemotherapy; CR: combined resection).
Figure 5
Figure 5
Test for publication bias. A. Begger’s test. B. Egger’s test.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Shibata A, Parsonnet J. In: Cancer Epidemiology and Prevention. 3. Schottenfeld D, Fraumeni JF, editor. New York: Oxford University Press; 2006. Stomach cancer; pp. 707–720.
    1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108. doi: 10.3322/canjclin.55.2.74. - DOI - PubMed
    1. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W. et al.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215–221. doi: 10.1016/S1470-2045(08)70035-4. - DOI - PubMed
    1. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H. et al.Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8(2):163–168. doi: 10.1023/A:1008243606668. - DOI - PubMed
    1. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71(3):587–591. doi: 10.1038/bjc.1995.114. - DOI - PMC - PubMed

Publication types